These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32056180)
41. Circulating Cell-Free DNA Levels Could Predict Oncological Outcomes of Patients Undergoing Esophagectomy for Esophageal Squamous Cell Carcinoma. Hsieh CC; Hsu HS; Chang SC; Chen YJ Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999323 [TBL] [Abstract][Full Text] [Related]
42. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724 [TBL] [Abstract][Full Text] [Related]
43. Urine-Based Liquid Biopsy for Nonurological Cancers. Jain S; Lin SY; Song W; Su YH Genet Test Mol Biomarkers; 2019 Apr; 23(4):277-283. PubMed ID: 30986103 [TBL] [Abstract][Full Text] [Related]
44. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
45. SET domain-containing 5 is a potential prognostic biomarker that promotes esophageal squamous cell carcinoma stemness. Piao L; Li H; Feng Y; Yang Z; Kim S; Xuan Y Exp Cell Res; 2020 Apr; 389(1):111861. PubMed ID: 31981592 [TBL] [Abstract][Full Text] [Related]
46. Poor prognostic impact of FGF4 amplification in patients with esophageal squamous cell carcinoma. Huang J; Song Q; Wang H; Wang H; Xu C; Wang X; Jiang Z; Wang Y; Xu Y; Su J; Zeng H; Tan L; Zhu H; Jiang D; Hou Y Hum Pathol; 2018 Oct; 80():210-218. PubMed ID: 29936056 [TBL] [Abstract][Full Text] [Related]
47. Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma. Nakagaki T; Tamura M; Kobashi K; Omori A; Koyama R; Idogawa M; Ogi K; Hiratsuka H; Tokino T; Sasaki Y Tumour Biol; 2018 Sep; 40(9):1010428318800180. PubMed ID: 30226113 [TBL] [Abstract][Full Text] [Related]
48. Exosomes-derived miR-154-5p attenuates esophageal squamous cell carcinoma progression and angiogenesis by targeting kinesin family member 14. Shou Y; Wang X; Liang Y; Liu X; Chen K Bioengineered; 2022 Feb; 13(2):4610-4620. PubMed ID: 35156510 [TBL] [Abstract][Full Text] [Related]
49. Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs. Casagrande GMS; Silva MO; Reis RM; Leal LF Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768828 [TBL] [Abstract][Full Text] [Related]
50. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Geeurickx E; Hendrix A Mol Aspects Med; 2020 Apr; 72():100828. PubMed ID: 31711714 [TBL] [Abstract][Full Text] [Related]
51. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same? Kahlert C Cancer Res; 2019 May; 79(10):2462-2465. PubMed ID: 31043377 [TBL] [Abstract][Full Text] [Related]
52. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes. Yang WY; Feng LF; Meng X; Chen R; Xu WH; Hou J; Xu T; Zhang L Expert Rev Mol Diagn; 2020 Dec; 20(12):1213-1227. PubMed ID: 33232189 [No Abstract] [Full Text] [Related]
53. Liquid Biopsy: A New Tool in Oncology. Costa JL; Schmitt FC Acta Cytol; 2019; 63(6):448. PubMed ID: 31266005 [No Abstract] [Full Text] [Related]
54. Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review. Olmedillas-López S; Olivera-Salazar R; García-Arranz M; García-Olmo D Mol Diagn Ther; 2022 Jan; 26(1):61-87. PubMed ID: 34773243 [TBL] [Abstract][Full Text] [Related]
55. Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature. van Ginkel JH; Slieker FJB; de Bree R; van Es RJJ; Van Cann EM; Willems SM Oral Oncol; 2017 Dec; 75():8-15. PubMed ID: 29224828 [TBL] [Abstract][Full Text] [Related]
56. Mechanisms of function and clinical potential of exosomes in esophageal squamous cell carcinoma. Zhao L; Yu L; Wang X; He J; Zhu X; Zhang R; Yang A Cancer Lett; 2023 Jan; 553():215993. PubMed ID: 36328162 [TBL] [Abstract][Full Text] [Related]
57. The scope of liquid biopsy in the clinical management of oral cancer. Baby NT; Abdullah A; Kannan S Int J Oral Maxillofac Surg; 2022 May; 51(5):591-601. PubMed ID: 34462176 [TBL] [Abstract][Full Text] [Related]
58. Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. Tanaka H; Kanda M; Koike M; Iwata N; Shimizu D; Ezaka K; Sueoka S; Tanaka Y; Takami H; Hashimoto R; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Fujiwara M; Kodera Y Int J Oncol; 2015 Nov; 47(5):1811-8. PubMed ID: 26397940 [TBL] [Abstract][Full Text] [Related]
59. Blood-based biomarkers for early detection of esophageal squamous cell carcinoma. Chu LY; Peng YH; Weng XF; Xie JJ; Xu YW World J Gastroenterol; 2020 Apr; 26(15):1708-1725. PubMed ID: 32351288 [TBL] [Abstract][Full Text] [Related]
60. Musashi1, a potential prognostic marker in esophageal squamous cell carcinoma. Qin G; Lian J; Yue D; Chen X; Nan S; Qi Y; Li B; Cui G; Li X; Zhao S; Zhang Y Oncol Rep; 2017 Sep; 38(3):1724-1732. PubMed ID: 28713964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]